Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
40 hedge funds and large institutions have $4.6M invested in Finch Therapeutics Group, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 5 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 43 → 40 (-3)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
73% less capital invested
Capital invested by funds: $16.8M → $4.6M (-$12.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$111K |
| 2 |
Renaissance Technologies
New York
|
+$91.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.42K |
| 5 |
BlackRock
New York
|
+$1.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Aperture Investors
New York
|
-$322K |
| 2 |
MP
MSD Partners
New York
|
-$262K |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
-$116K |
| 4 |
SCM
SCS Capital Management
Boston,
Massachusetts
|
-$64K |
| 5 |
Millennium Management
New York
|
-$52.2K |
FNCH Hedge Fund Activity: Q4 2022 in Review
40 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q4 2022, worth a combined $4.6M — down 73% from $16.8M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of FNCH and 2 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 5 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $111K. The largest seller was Aperture Investors, exiting entirely with an estimated $322K sold.
- 40 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q4 2022, down from 43 in Q3 2022.
- Funds reported $4.6M of Finch Therapeutics Group, Inc. Common Stock stock for Q4 2022, down 73% quarter-over-quarter.
- 2 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q4 2022 and 5 closed out, a net change of -3 holders.
- The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q4 2022 was Bridgeway Capital Management, an estimated $111K added.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q4 2022 was Aperture Investors, an estimated $322K sold.
Based on aggregated 13F filings for Q4 2022.